Loss of antibodies, but not of protection

The Lancet Infectious Diseases

Volumn 10, Issue 11, 2010, Pages 738-739

  Wenzel, Jürgen J ^a   Jilg, Wolfgang ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIBODY TITER; DIPHTHERIA; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNIZATION; INFLUENZA; LETTER; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; TETANUS;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; POLIOVIRUS VACCINE, INACTIVATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, COMBINED;

EID: 78049354559     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70217-6     Document Type: Letter

References (13)

1. Zanetti AR, Romanò L, Giambi C, et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010, 10:755-761.
2. Scientific conclusions and grounds for the suspension of the marketing authorisation of Hexavac presented by the EMEA European Medicines Agency, (accessed June 26, 2009). http://www.emea.europa.eu/humandocs/PDFs/EPAR/Hexavac/Hexavac-H-298-Z-28-en.pdf.
3. Questions and answers on the suspension of hexavac. London European Medicines Agency, (accessed Oct 4, 2010). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500017700.pdf.
4. Tichmann I, Preidel H, Grunert D, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005, 23:3272-3279.
5. Tichmann I, Grunert D, Habash S, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type B vaccines and evaluation of booster vaccination. Hum Vaccin 2006, 2:249-254.
6. Reinert P, Cinquetti S, Soubeyrand B, et al. Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine. Adv Ther 2010, 27:28-38.
7. Jilg W, Schmidt M, Deinhardt F Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988, 6:201-207.
8. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565. European Consensus Group on Hepatitis B Immunity.
9. Banatvala J, Van Damme P, Oehen S Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19:877-885.
10. Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15:1-8.
11. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007, 25:6958-6964.
12. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120:373-381.
13. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197:1419-1426.